Drug intelligence / Profile preview

Prostate Acid Phosphatase

Development stage: Unknown
Lead developer: Madison Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Oral, Intracutaneous, Subcutaneous, Intramuscular, Intravenous

Overview

Prostate Acid Phosphatase (PAP) is an antigen targeted by a vaccine for non-metastatic prostate cancer. The vaccine aims to enhance the patient's immune response against cancer. In the context provided, it is studied in combination with GM-CSF (Granulocyte-macrophage colony-stimulating factor) to boost the immune response.

Targets

PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on Prostate Acid Phosphatase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostate Acid Phosphatase.

Explore the full profile